+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Recent advances in PET probes for hepatocellular carcinoma characterization



Recent advances in PET probes for hepatocellular carcinoma characterization



Expert Review of Medical Devices 2019



Positron Emission Tomography (PET) with 18F-fluorodeoxyglucose (FDG) presents some limitations for imaging of hepatocellular carcinoma (HCC), the most common primary hepatic malignancy. Areas covered: The authors discuss the accuracy and limitations of FDG for HCC detection. Then, authors examine the recent advances in PET tracers other than FDG for the biological and prognostic characterization of HCC such as 11C-acetate, 11C-choline and its 18F-labeled derivatives. Expert commentary: FDG PET can be helpful for the identification of the more aggressive and poorly differentiated HCC. 11C-acetate is readily incorporated into intracellular phosphatidylcholine membranes and proved useful for the in vivo biological characterization of the more differentiated and less aggressive HCC. Nevertheless, the short half-life of 11C- radionuclide limits the clinical application of this compound. 11C-choline, another surrogate biomarker of cell membrane biosynthesis, has been demonstrated effective for HCC imaging. The availability of choline derivatives labelled with 18F-radionuclide (i.e. 18F-fluoroethylcholine, 18F-fluorocholine) has overcome the drawbacks due to 11C, thus triggering the clinical applications of choline PET for HCC diagnosis and management. Further research needs to be conducted to better define the alternative or complementary role of these PET probes for the characterization of HCC, with particular regard to the dual-tracer PET-CT modality.

(PDF emailed within 0-6 h: $19.90)

Accession: 066695598

Download citation: RISBibTeXText

PMID: 30990129

DOI: 10.1080/17434440.2019.1608817


Related references

Recent Advances in Magnetic Nanoparticle-based Molecular Probes for Hepatocellular Carcinoma Diagnosis and Therapy. Current Pharmaceutical Design 24(21): 2432-2437, 2018

Recent advances and controversies in surgical management of hepatocellular carcinoma of hepatocellular carcinoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 30(4): 378-380, 2008

Recent advances in target characterization and identification by photoaffinity probes. Molecules 18(9): 10425-10451, 2014

Recent advances in the treatment of hepatocellular carcinoma. Current Opinion in Gastroenterology 29(3): 285-292, 2013

Recent advances in the treatment of hepatocellular carcinoma. Nihon Shokakibyo Gakkai Zasshi 112(1): 18-23, 2016

Recent advances in the imaging of hepatocellular carcinoma. Clinical and Molecular Hepatology 21(1): 95-103, 2015

Recent advances in the treatment of hepatocellular carcinoma. Current Opinion in Gastroenterology 26(3): 189-195, 2010

Recent advances in the study of hepatocellular carcinoma. Keio Journal of Medicine 41(4): 195-204, 1992

Recent advances in the classification of hepatocellular carcinoma. Diagnostic Histopathology 18(1): 37-45, 2012

Recent advances in the diagnosis of hepatocellular carcinoma. Hepatology Research 37 Suppl 2: S178-S192, 2007

Recent advances in the management of hepatocellular carcinoma. Journal of B.U.On. 21(2): 307-311, 2016

Recent advances in hepatocellular carcinoma therapy. Pharmacology and Therapeutics 173: 106-117, 2017

Recent advances in multidisciplinary management of hepatocellular carcinoma. World Journal of Hepatology 7(4): 673-687, 2015

Recent advances in ultrasonographic diagnosis of hepatocellular carcinoma. Cancer 63(7): 1313-1317, 1989

Recent advances in surgical treatment of hepatocellular carcinoma. Drug Discoveries and Therapeutics 9(5): 319-330, 2016